Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
J Clin Oncol · 2025-Mar · PMID 39647999
OS
FIG 1. PFS and OS in zanubrutinib- and BR-treated patients (ITT). HRs and 95% CIs were based on a stratified Cox regression model with the BR arm as the reference group; stratification factors were age ( < 65 years v ≥65 years), Binet stage (C v A or B), and IGHV gene mutational status (mutated v unmutated). All P values were one-sided and descriptive. (A) PFS in the overall population; (B) PFS in patients with mutated and unmutated IGHV genes; (C) PFS in the overall population adjusted for COVID-19; (D) OS in the overall population; (E) OS in the overall population adjusted for COVID-19. BR, bendamustine plus rituximab; HR, hazard ratio; IGHV, immunoglobulin heavy-chain variable region; ITT, intention-to-treat; OS, overall survival; PFS, progression-free survival.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-23T18:08:23+00:00 |